相关实验视频
Updated: Jan 9, 2026

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
977
PD-1,BTLA和TIGIT作为类风湿性疾病的治疗点
Juhi R Kuchroo1,2, Naomi Goldman1,2, Arlene H Sharpe3,4
1Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Nature reviews. Rheumatology
|December 2, 2025
概括
免疫检查点分子如PD-1,BTLA和TIGIT调节免疫反应. 针对这些检查点显示,通过诱导免疫耐受性来治疗自身免疫性疾病具有前景.
科学领域:
- 免疫学 免疫学 免疫学
- 这是一种自身免疫力.
- 癌症免疫疗法癌症免疫疗法
背景情况:
- 免疫检查点分子对于平衡免疫反应和预防自身免疫性至关重要.
- 调节免疫检查点影响瘤特异性和自我特异性免疫反应,如癌症治疗和免疫治疗副作用中所见.
- 对针对自身免疫和风湿性疾病的免疫检查点越来越感兴趣.
研究的目的:
- 探索针对自身免疫性疾病的免疫检查点分子的治疗潜力.
- 研究PD-1,BTLA和TIGIT在诱导免疫耐受性的作用.
- 突出了解这些分子在免疫细胞中的功能对于临床翻译的重要性.
主要方法:
- 临床前模型被用来测试免疫检查点分子的向.
- 对一些向性免疫检查点分子启动了临床试验.
- 重点是对不同疾病的免疫细胞群体,特别是T细胞的分析.
主要成果:
- 准免疫检查点分子PD-1,BTLA和TIGIT在临床前环境中显示出治疗前景.
- 一些向性免疫检查点疗法已经进入临床试验.
- 这些受体的调节极大地影响了免疫反应.
结论:
- 针对PD-1,BTLA和TIGIT等免疫检查点提供了一个有希望的策略,用于诱导自身免疫性疾病中的免疫耐受性.
- 对各种免疫细胞和疾病中的免疫检查点受体功能的彻底理解对于成功的临床应用至关重要.
- 需要进一步的研究才能将这些发现完全转化为对自身免疫疾病的有效治疗方法.
相关概念视频
Rheumatic Heart Disease III: Medical Management
267
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
267
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
418
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
418
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K

